

1
2
3
4 IRE1 α -XBP1 Activation Elicited by Viral Singled Stranded RNA via TLR8
5 May Modulate Lung Cytokine Induction in SARS-CoV-2 Pneumonia
6

7 José J. Fernández¹, Cristina Mancebo^{1,2}, Sonsoles Garcinuño³, Gabriel March³, Yolanda
8 Alvarez^{1,2}, Sara Alonso¹, Luis Inglada⁴, Jesús Blanco^{5,6}, Antonio Orduña³, Olimpio Montero¹,
9 Tito A. Sandoval^{7,8,9}, Juan R. Cubillos-Ruiz^{7,8,9}, Elena Bustamante¹⁰, Nieves Fernández^{1,2,¶},
10 Mariano Sánchez Crespo^{1¶*}

11
12 ¹Unidad de Excelencia Instituto de Biología y Genética Molecular, CSIC-Universidad de
13 Valladolid, Spain

14
15 ²Departamento de Bioquímica, Biología Molecular y Fisiología, Universidad de Valladolid,
16 Spain

17
18 ³Servicio de Microbiología, Hospital Clínico Universitario de Valladolid, Universidad de
19 Valladolid, Spain

20
21 ⁴Servicio de Medicina Interna, Hospital Universitario Rio-Hortega, Valladolid, Spain

22
23 ⁵Servicio de Medicina Intensiva, Hospital Universitario Rio-Hortega, Valladolid, Spain

24
25 ⁶CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

26
27 ⁷Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY,
28 10065, USA

29
30 ⁸Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, 10065,
31 USA


32
33 ⁹Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, 10065,
34 USA

35
36 ¹⁰Servicio de Medicina Intensiva, Hospital Clínico Universitario de Valladolid, Spain

37
38
39 * Corresponding author
40 E-mail: sanchezcrespomariano@gmail.com (M.S.C.)

41
42 ¶These authors contributed equally to this work.
43
44
45
46
47
48
49

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74



75

76 Abstract

77

78 Initial symptoms of COVID-19 infection depend on viral replication, while hyperinflammation
79 is a hallmark of critical illness and may drive severe pneumonia and death. Among the
80 mechanisms potentially involved in the hyperinflammatory state, we focused on the unfolded
81 protein response, because the IRE1 α -XBP1 branch can be activated as result of the
82 endoplasmic reticulum stress produced by the overwhelming synthesis of viral components and
83 synergizes with Toll-like receptor signaling to induce cytokine expression. Viral RNA may
84 trigger the IRE1 α -XBP1 branch via TLR7/8 activation and like TLR2 and TLR4 may underpin
85 cytokine expression trough *XBP1* splicing (*sXBP1*). The expression of *IL1B*, *IL6*, and *TNF*

86 mRNA in bronchoalveolar aspirates (BAAs) were higher in COVID-19 patients under
87 mechanical ventilation and intubation who showed *sXBPI*. The scrutiny of
88 monocytic/macrophagic markers during active infection showed a reduction of those involved
89 in antigen presentation and survival, as well as the IFN stimulated gene *MXI*. These changes
90 reverted after infection tests turned negative. In contrast, the expression of the mRNA of the
91 serine protease *TMPRSS2* involved in S protein priming showed a high expression during
92 active infection. *TLR8* mRNA showed an overwhelming expression as compared to *TLR7*
93 mRNA, which suggests the presence of monocyte-derived dendritic cells (MDDCs). *In vitro*
94 experiments in MDDCs activated with ssRNA40, a positive-sense, single-stranded RNA
95 (+ssRNA) like SARS-CoV-2 RNA, induced *sXBPI* and the expression of IL-1 β , IL-6, and
96 TNF α at mRNA and protein levels. These responses were blunted by the IRE1 α ribonuclease
97 inhibitor MKC8866. Given the analogies between the results observed in BAAs and the effects
98 induced by +ssRNA in MDDCs, IRE1 α ribonuclease inhibition might be a druggable target in
99 severe COVID-19 disease.

100

101

102 **Author summary**

103

104 COVID-19 pandemics put an unprecedented pressure on health systems. The need of new
105 therapies urged research on the mechanisms triggered by the interaction of SARS-CoV-2 virus
106 with host cells and the ensuing pathophysiology driving pneumonia and multiorgan failure.
107 Hyperinflammation soon appeared as a mechanism involved in mortality that could even
108 proceed after viral infection comes to an end. Hyperinflammation is supported by an
109 inappropriate production of cytokines, and this explains the use of the term cytokine storm to
110 refer to this phase of the disease.

111 Given that insight into the molecular mechanisms driving cytokine storm should focus on the
112 interaction of viral components with immune cells, experiments addressing the effect of viral
113 components on its cognate receptors were carried out. It was observed that viral RNA induces
114 a cytokine pattern like the one observed in bronchoalveolar aspirates of COVID-19 patients
115 with critical disease. Overall, the study revealed that both cell organelle overload and receptors
116 involved in the recognition of viral RNA may team up to induce proinflammatory cytokines.
117 This mechanism can be exploited to develop new treatments for COVID-19 disease.

118

119 **Introduction**

120

121 Coronavirus disease 2019 (COVID-19) is a pandemic infection produced by severe acute
122 respiratory syndrome coronavirus 2 (SARS-CoV-2). Habitual evolution includes an initial
123 influenza-like phase where fever and unproductive cough are predominant, but it can lead to
124 severe respiratory insufficiency and multiorgan failure, which in many cases proceeds after
125 infection resolution due to a hyperinflammatory response associated with the production of
126 proinflammatory cytokines. The term cytokine storm was coined to refer to this condition [1],
127 but the analysis of the immunopathological damage and the analogies with other viral diseases
128 make it most appropriate the use of viral sepsis to depict the association of T-cell deficiencies
129 with systemic hyperinflammation driven by virus-host cell interaction [2]. The use by viruses
130 of the translational machinery of the host to produce their materials overloads many cellular
131 functions, including protein folding and secretion in the endoplasmic reticulum (ER). Since
132 only properly folded proteins should exit from the ER to maintain homeostasis, cells arrange a
133 response directed to retain and degrade defective proteins. This involves an intracellular
134 signaling pathway termed the unfolded protein response (UPR) [3-5]. The UPR includes a
135 down regulation of global protein synthesis, the degradation of some proteins, and the
136 transcriptional induction of specific genes associated with the activity of its three branches.
137 The most conserved one depends on the dual activity of inositol-requiring enzyme 1 α (IRE1 α),
138 which shows protein kinase and endonuclease activities [6]. The endonuclease activity cleaves
139 a 26- base fragment of the mRNA of the preformed transcript of *XBPI*, which is followed by
140 ligation of the resulting exons to yield *sXBPI*. This drives the translation of the functionally
141 active factor *sXBPI* that *trans*-activates genes encoding proinflammatory proteins, e.g., the
142 prostaglandin producing enzymes cyclooxygenase 2 and the microsomal isoform of

143 prostaglandin synthase 2 [7], the ubiquitin-like modifier ISG15, and the cytokines IFN β , IL-6,
144 IL-23, and TNF α [8-11].

145 Although the goal of the UPR is alleviating ER-stress, the IRE1 α -XBP1 branch
146 contributes to the pathogenesis of multiple ailments, including cancer, atherosclerosis,
147 infections, and autoimmune diseases [12-15]. Recent research has disclosed that the IRE1 α -
148 XBP1 branch enhances viral transcription and contributes to maintain dormant viral genomes
149 in a host of infections [16,17]. The notion that UPR branches can mediate immune recognition
150 of zoonotic viruses and drive acute lung injury through ER-stress mediated inflammation was
151 disclosed by Hrincius et al. [18], who showed activation of the UPR by infection with poorly
152 glycosylated pandemic strains of influenza A virus. The IRE1 α route was recruited, and its
153 activation reduced when glycans were added to specific sites in the globular head of
154 hemagglutinin. A study in cell lines infected with a SARS-CoV-2 isolate and lung biopsies of
155 COVID-19 patients showed that SARS-CoV-2 hijacks the glycosylation biosynthetic
156 machinery and drives ER-stress and UPR activation. This is due to the overwhelming
157 asparagine N-linked glycosylation required for the translation of viral glycoproteins, which
158 forces aberrant glycosylation and ER-stress [19]. In keeping with notion, specific activation of
159 sXBP1 has been reported in monocytes from COVID-19 patients [20].

160 The association of sXBP1 with TLR2 and TLR4 signaling [8] together with genuine
161 UPR induced by protein synthesis overload point to sXBP1 involvement in the cytokine storm.
162 [21]. The role of cytokine storm in COVID-19 disease was supported by the beneficial effect
163 of tocilizumab, a humanized antihuman IL-6 receptor antibody [22]. This is noteworthy given
164 the dependence of IL-6 production on the IRE1 α -XBP1 branch [8] and the presence in the
165 proximal promoter of *IL6* of at least six sequences binding to sXBP1 [23]. Another potential
166 interference of sXBP1 on COVID-19 illness stems from its blunting effect on dendritic cell
167 homeostasis and the metabolic fitness of T-cells [24,25]. Likewise, the σ 1 receptor (S1R)

168 reduces cytokine production in murine models of septic shock through IRE1 α endonuclease
169 activity inhibition [14]. A new piece of evidence associating the UPR with COVID-19 illness
170 was the induction of the UPR by ORF8 and S viral proteins, as well as the reduction of viral
171 replication by pharmacological inhibition of the IRE1 α and ATF6 branches in epithelial cell
172 lines [26]. In contrast, up-regulation of IRE1 α (RNase) activity by cannabidiol has been found
173 to block SARS-CoV-2 replication in a cell line derived from lung epithelial cells and in lungs
174 and nasal turbinates of infected mice [27].

175 Given that SARS-CoV-2 is a +ssRNA virus, the tandem TLR7/8 comes into
176 prominence given its ability to bind viral RNA. Consistent with this notion, loss-of-function
177 variants in X-chromosomal *TLR7* have been reported in young patients with severe COVID-
178 19 disease, who showed impaired type I and II IFN responses [28]. The purpose of this study
179 has been addressing how sXBP1 and TLR7/8 engagement may underpin viral sepsis in
180 COVID-19 disease. To this end, samples of nasopharyngeal swabs and bronchoalveolar
181 aspirates (BAAs) were studied to address the presence of *sXBP1*, the cytokine-signature, and
182 the expression of monocytic lineage cell markers and enzymes involved in energetic
183 metabolism. After obtaining a profile of the transcriptional landscape, *in vitro* experiments
184 were performed to address the transcriptional and energetic patterns of MDDCs stimulated with
185 TLR7 and TLR8 agonists. Experiments showed that TLR8 activation of MDDCs induces a
186 pattern of *XBPI* splicing and cytokine expression, sensitive to inhibition of IRE1 α RNase
187 activity, which mimics the pattern observed in BAAs.

188

189 **Results**

190

191 **Studies in Nasopharyngeal Samples**

192 Initial assays were conducted in nasopharyngeal samples from patients receiving medical
193 assistance for symptoms consistent with COVID-19 disease (Fig 1A). The extracted RNA was
194 used for the diagnosis of SARS-CoV-2 infection and residual samples used for the assay of
195 *sXBPI* by RT-PCR assays. This entails the separation of the PCR products by electrophoresis
196 in agarose gel and densitometric analysis of GelRed stained bands. *sXBPI* is distinguished
197 from unspliced *XBPI* (*uXBPI*) by its faster migration. The position of the primers and the
198 spliced region are shown in Fig 1B. These correspond to GenBank sequence
199 NM_001079539.2, which differs from *uXBPI* sequence NM_005080.4 by the deletion of 26
200 nucleotides. Separate sequencing of the bands was used to confirm splicing (Fig 1C). A
201 random selected array of RT-PCR negative and positive samples shows the presence of *uXBPI*
202 and *sXBPI* (Fig 1D). The presence of three bands in some cases is explained by the formation
203 of heteroduplexes [29]. *sXBPI* was detected in 17.91% of SARS-CoV-2 negative and 40.32%
204 of SARS-CoV-2 positive patients (Fig 1E). Quantitation of *sXBPI* showed higher values in
205 COVID-19 positive patients as compared to the negative ones (Fig 1F). The incidence of
206 *sXBPI* was similar in male and females (Fig 1G) and increased with age (Fig 1H). Mortality
207 was observed in four patients who showed a degree of splicing above 10% of total *XBPI* (Fig
208 1I). These findings show that *sXBPI* shows higher frequency and extent in nasopharyngeal
209 exudates of patients with active SARS-CoV-2 infection, particularly in dying patients.

210

211 ***sXBPI* and Cytokine Expression in BAAs**

212 Further experiments were carried out using RNA extracted from BAAs of patients under
213 mechanical ventilation in intensive care unit (ICU) (Fig. 2A). Ventilatory support and

214 endotracheal intubation were indicated because of acute hypoxemic respiratory failure despite
215 high-flow nasal oxygen therapy or non-invasive ventilation. COVID-19 patients received a
216 standard and proved useful treatment for the hyperinflammatory state consisting of 6 mg
217 dexamethasone daily or 50 mg of IV hydrocortisone every 8 hours for up to 10 days, while this
218 protocol was not routinely used in non-COVID-19 patients (Fig 2B). The extent of *sXBP1* was
219 higher in SARS2-CoV-2 pneumonia patients than in those with respiratory failure due to other
220 conditions, decreased after COVID-19 tests turned negative, and showed higher values than
221 those observed in nasopharyngeal swabs (Fig 2C). The PERK-eIF2 α -ATF4-CHOP branch of
222 the UPR was explored assaying *DDIT3/CHOP* gene expression. *DDIT3* expression also
223 decreased after SARS-CoV-2 tests turned negative, while there was no significant difference
224 of expression between non-COVID-19 and COVID-19 pneumonia patients (Fig 2D). As
225 regards cytokine expression (Fig 2E-2N), *IL1B* and *IL6* mRNA levels during viral proliferation
226 were significantly lower than those detected in non-COVID-19 patients. A similar trend was
227 observed in *TNF*, *IL23A*, and *IL8* mRNA expression, although these values did not reach
228 statistical significance. Cytokine mRNA did not show a trend to decrease after SARS-CoV-2
229 tests were negative. *IL10* and *IFNB* mRNA were higher in SARS-CoV-2 infection than in non-
230 COVID pneumonia and continued elevated after COVID-19 tests turned negative. *IFNG*
231 showed a trend to be increased in COVID-19 pneumonia. Overall, these results show that
232 *sXBP1* in respiratory samples from COVID-19 patients does not associate with levels of
233 cytokine expression higher than those observed in non-COVID-19 pneumonias. The high
234 expression of *IL10* mRNA suggests a parallel activation of an archetypal anti-inflammatory
235 cytokine that might counter the inflammatory response. The increased expression of *IFNBI*
236 mRNA is consistent with its involvement in viral sepsis.

237

238 ***sXBP1* Stratification in SARS-CoV-2 Patients during ICU Hospitalization**

239 SARS-CoV-2 patients were stratified according to the presence or absence of both active
240 infection and *sXBP1*. Fig 3A shows viral load in samples collected during infection and at the
241 time when a negative COVID-19 test was first recorded. *PTGS2* mRNA was higher in patients
242 with *sXBP1* both during infection and after negativization of the RT-PCR test (Fig 3B). *TNF*
243 and *IL1B* mRNA expression was also higher in patients with *sXBP1*, even after a negative RT-
244 PCR test (Fig 3C and 3D). *IL6* mRNA was increased in patients with *sXBP1* and active
245 infection (Fig 3E). *IL8* mRNA was expressed at much lower levels than those encoding other
246 cytokines, particularly after negativization of the infection in patients who did not show *sXBP1*
247 (Fig 3F). *IL10* mRNA was higher in SARS-CoV-2 positive patients who did not show *sXBP1*
248 and remained elevated in patients showing *sXBP1* after resolution of the infection. These
249 results show a high expression of the mRNA of *PTGS2* and several proinflammatory cytokines
250 in patients with *sXBP1*, which may persist after SARS-CoV-2 test becomes negative. The
251 sustained expression of *PTGS2* (COX2) mRNA suggests its involvement in either induction or
252 repair of inflammatory damage [30]. Together, the results agree with the reported role of
253 *sXBP1* in the transcriptional activation of COX2, TNF α , IL-1 β , and IL-6.

254

255 **Expression of Genes Involved in Glycolysis and Oxidative Phosphorylation (OXPHOS)**

256 Lymphocytes and myeloid cells respond to pathogen-associated molecular patterns (PAMPs)
257 with a robust rewiring of their energetic metabolism driving increased glycolysis (Fig 4A). The
258 impairment of O₂ supply due to pneumonia further explains the resort to glycolysis and agrees
259 with reports showing that SARS-CoV-2-induced metabolic reprogramming enhances the
260 production of proinflammatory cytokines and IFNs by monocytes, and concomitantly inhibits
261 T cell function [31,32]. Consistent with this notion, the expression of *GLUT1* mRNA, a glucose
262 transporter, and *HIF1A* mRNA, a transcription factor involved in the regulation of glycolytic
263 enzymes, were increased during active infection. However, there was no difference as

264 compared to non-COVID-19 pneumonia (Fig 4B and 4C). The mRNA encoding hexokinase II
265 (Fig 4D), pyruvate dehydrogenase kinase IV (Fig 4F), malate dehydrogenase (MD) 2 (Fig 4G),
266 and *cis*-aconitate dehydrogenase (*IRG1* gene) (Fig 4K) increased during active infection as
267 compared to both non-COVID-19 pneumonia and post-COVID infection. Notably, proteins
268 involved in mitochondrial function also increased during COVID-19 pneumonia, i.e., succinate
269 dehydrogenase subunit A (Fig 4I) and the 2-oxoglutarate-malate transporter SLC25A11, (Fig
270 4J). Together, these data show a resort to glycolysis during active SARS-CoV-2 infection that
271 seems supported by the activity of HIF1 and elements of the malate-aspartate shuttle such as
272 MD2 and SLC25A11, which buttress the NAD⁺/NADH redox balance necessary for the
273 progression of glycolysis at the glyceraldehyde 3-phosphate-dehydrogenase step.

274

275 **Characterization of Monocytic Markers in BAAs**

276 The first attempt to characterize the monocytic/macrophagic populations in BAAs focused on
277 the expression of TLR7/8, given their involvement in the recognition of viral RNA. *TLR8*
278 mRNA was expressed to a far greater extent than *TLR7* mRNA (Fig 5A), which agrees with
279 the decay of *TLR7* expression during the differentiation to MDDCs [33]. Further assay of
280 markers showed a diminished expression of *HLA-DRB1* (Fig 5B), a gene involved in antigen
281 presentation, *CD300E* (Fig 5C), a gene associated with survival signals, the chemokine
282 receptor *CCR2* (Fig 5D), and the IFN-stimulated gene (ISG) *MX1*, (Fig 5G). Negativization of
283 viral replication was associated with an increase of the expression of these genes, as well as
284 the migration receptor *MMP9* (Fig 5E) and the MDDC differentiation marker *BATF3* (Fig 5F).
285 *PTGS2/COX2* mRNA was similar in non-COVID and active COVID infection and decreased
286 after RT-PCR test became negative (Fig 5I). The mRNA of the ISG *OAS1* did not show
287 significant changes during SARS-CoV-2 infection and increased after negativization of SARS-
288 CoV-2 test (Fig 5H). *TMPRSS2* mRNA, a serine protease involved in the cleavage of viral

289 spike proteins [34] was significantly increased during SARS-CoV-2 active infection and (Fig
290 5J). These results disclose a differentiation profile during COVID-19 infection characterized
291 by a low expression of markers associated with antigen presentation and survival signals, as
292 well as *MXI*. This is followed by an increase of the markers expressed in MDDCs in response
293 to TLR ligands [33]. The high expression of *TMPRSS2* mRNA underscores the role of
294 *TMPRSS2* in SARS-CoV-2 cell invasion and the low expression of *MXI* agrees with the
295 reported association of single nucleotide polymorphisms within *TMPRSS2* and near *MXI* gene
296 with severe COVID-19 disease [35]. A cogent explanation for the low *MXI* expression could
297 be an evasive strategy of SARS-CoV-2 to avoid and/or shut down type I IFN responses [36].

298

299 **Effects Induced by the Stimulation of Receptors Involved in the Recognition of Viral** 300 **RNAs in MDDCs**

301 Because SARS-CoV-2 is a +ssRNA virus, we posited that TLR7/8 might shape the innate
302 immune response, given their endosomal location and accessibility to intracellular viral RNA.
303 *TLR7* and *TLR8* expression in MDDCs mimicked the pattern observed in BAAs by showing a
304 high expression of *TLR8* and a low expression of *TLR7* mRNA (Fig 6A). Activation of TLR7
305 by the selective ligand imiquimod showed a low extent of *XBPI* splicing, even in real-time
306 RT-PCR assays using a reverse primer overlapping the spliced region (Fig 6B). Consistent with
307 the effect of palmitate as a potentiator of imiquimod effect via metabolic rewiring and *XBPI*
308 splicing [11], the expression of proinflammatory cytokines increased in the presence of
309 palmitate (Fig 6C-6F). In contrast, 2-deoxyglucose, which enhances *XBPI* splicing in the
310 presence of some PAMPs [10] showed a limited effect. Given that IFN γ teams up with TNF α
311 to induce mortality in mice during SARS-CoV-2 infection [37] and it has been associated with
312 the development of cytokine storm [38-41], the expression of ISGs was assayed. In contrast to
313 IFNs, *MXI* and *OAS1* showed high levels of expression. The IRE1 α RNase inhibitor MKC8866

314 [42] and the S1R agonist fluvoxamine, which has been reported to inhibit *XBPI* splicing in
315 bacterial sepsis [14], lacked any significant effect on those responses (Fig 6G-6J). Real-time
316 assays of energetic metabolism with the Seahorse technology, showed a reduction of O₂
317 consumption rate (OCR) and an increased extracellular acidification rate (ECAR) in response
318 to imiquimod (Fig 6K), thus mimicking the glycolytic rewiring induced by bacterial PAMPs
319 [43]. These effects were enhanced by metformin, a well-known inhibitor of the complex I of
320 the electron transport chain (Fig 6L) that has been associated with a beneficial effect on the
321 evolution of COVID-19 disease [44], most likely explained by its ability to reduce IL-1 β and
322 enhance IL-10 production [45]. Poly(cytidylic-inosinic) acid (poly(I:C)), a polyribonucleotide
323 that mimics the effects of viral double-stranded RNA and activates TLR3, did not show any
324 significant effect (Fig 6M).

325 In contrast to the limited effect of imiquimod, the TLR8 agonist ssRNA40, a 20-mer
326 phosphorothioate protected single-stranded RNA oligonucleotide containing a GU-rich
327 sequence, induced *sXBPI* in a similar way to the effect of the TLR2 agonist zymosan. The
328 splicing was blocked by the IRE1 α RNase inhibitors MKC8866 and 4 μ 8C (Fig 7A). MKC8866
329 also inhibited the expression of *IL1B*, *IL6*, and *TNF* mRNA (Figs 7B-7D) and protein (Fig 7E-
330 7F), thus resembling the cytokine signature detected in BAAs. ssRNA41, a ssRNA40
331 derivative wherein uracil nucleotides are replaced with adenosine and does not activate TLR8-
332 dependent signaling, did not induce cytokine expression, induced *sXBPI* to a low extent, and
333 was less active than ssRNA40 to induce the aggregation of misfolded proteins, as deemed from
334 the assay of aggresomes (S1A and S1B Fig). While pro-IL-1 β expression increased in response
335 to ssRNA40 (Fig 7G), IL-1 β was not detected in MDDCs supernatants, thus suggesting that
336 ssRNA40 does not activate the inflammasome and that an additional signal(s) is required for
337 IL-1 β secretion. The expression of IL-6 and TNF α protein was inhibited by both MKC8866
338 and fluvoxamine, which suggests that *sXBPI* plays a significant role on the transcription of

339 these cytokines. *IFNB1*, *MX1*, and *OAS1* mRNA were also induced by ssRNA40, while both
340 MKC8866 and fluvoxamine only inhibited *MX1* and *OAS1* expression (Fig 7H-7K), thus
341 suggesting a direct effect of sXBP1 on *MX1* and *OAS1* expression, rather than an indirect effect
342 mediated by IFNs. Notably, ssRNA40 did not modify the energetic pattern of MDDCs (S1C
343 Fig), which indicates that its ability to induce cytokine expression does not depend on blatant
344 energetic changes. Unlike ssRNA40, zymosan, a ligand of TLR2 and C-type lectin receptors
345 that mimics the external wall of fungi, induced a robust induction of glycolysis and OXPHOS
346 as deemed from ECAR and OCR increases, respectively (S1D Fig).

347 To confirm the involvement of sXBP1 in the transcriptional activation of cytokines, its
348 binding to the proximal promoter regions of *IL1B*, *IL6*, and *TNF* was assayed. Chromatin
349 immunoprecipitation (ChIP) assays were conducted with primers spanning areas including
350 consensus *cis*-regulatory elements associated with position weight matrices discovered in
351 sXBP1 target promoters [23]. An increased binding of sXBP1 to the regions indicated in Fig
352 7L-N was observed after one hour of stimulation by ssRNA40. These results show that PAMPs
353 acting on TLR8 induce a cytokine signature like that observed in BAAs and point to the central
354 involvement of MDDCs in the innate immune response to SARS-CoV-2. The presence of
355 *sXBP1* in nasopharyngeal swabs and BAAs, its induction by ssRNA40 in MDDCs, the effect
356 of IRE1 α RNase inhibition on the cytokine induction produced by ssRNA40, and the
357 demonstration of sXBP1 binding to the *IL1B*, *IL6*, and *TNF* promoters suggest that TLR8-
358 induced *XBPI* splicing may contribute to the viral sepsis observed in severe cases of COVID-
359 19 disease.

360 **Discussion**

361

362 Current pathogenetic views on COVID-19 pneumonia focus on immunopathological damage
363 due to an exuberant innate immune response and a poor adaptive response. Assay of respiratory
364 secretions allows the identification of the pathogens and can also give cues on pathogenesis
365 [46-48]. This approach has been used in COVID-19 disease after the seminal studies by Zhou
366 et al. [49] and Liao et al. [50], who used bronchoscopy and lavage to identify immune cell
367 types in the respiratory tract. Our study focussed on patients under mechanical ventilatory
368 support due to severe pneumonia, whose samples were obtained during routine care by
369 attending staff [51-53]. This is in line with the use of tracheal aspirates to assess the
370 transcriptional profiling of the lower respiratory tract in critically ill COVID-19 patients [54].
371 Initial assays showed higher degrees of *sXBP1* in COVID-19 disease than in patients with non-
372 SARS-CoV-2 infection, although the mRNA levels of proinflammatory cytokines were higher
373 in patients undergoing bacterial pneumonia. This was not fully unexpected, since cytokine
374 storm is influenced by genetics and physiological conditions, in addition to cytokine levels
375 [55,56]. Moreover, COVID-19 patients received steroids in a regular schedule, which
376 contributes to reduce proinflammatory cytokines, and showed an overall mortality lower than
377 that observed in non-COVID patients. Notably, inhibition of IRE1 α activity through activation
378 of SIR by fluvoxamine protected mice from mortality during endotoxemia and fecal-induced
379 peritonitis, as well as the production of IL-1 β , IL-6, and IL-12 p40 by human leukocytes [14].
380 Consistent with the experimental results, early fluvoxamine treatment in individuals with mild
381 COVID-19 illness was associated with a reduction of signs of clinical deterioration as
382 compared to the placebo group [57]. Similar results were reported in the TOGETHER trial,
383 which involved larger cohorts for study and showed a significant reduction of morbidity by
384 fluvoxamine, as deemed from a reduced resort to either retention in a COVID-19 emergency

385 setting or transfer to tertiary hospital. Consistent with these findings, an independent data safety
386 monitoring committee recommended stopping randomly assigning patients to the fluvoxamine
387 arm in view of the superiority criterion for the primary endpoint [58]. Stratification of patients
388 showing active infection and *sXBPI* disclosed the association of *sXBPI* with higher levels of
389 cytokine expression and their decrease after infection negativization, thus suggesting that the
390 effect of fluvoxamine may be due to inhibition of the IRE1 α -XBP1 branch.

391 Secondary goals of the study were the characterization of enzymes involved in the
392 bioenergetics and the identification of myeloid-lineage differentiation footprints. Bioenergetic
393 screening suggested active glycolysis during SARS-CoV-2 infection supported by HIF1 and
394 elements of the malate-aspartate shuttle. However, the predominance of glycolytic enzymes
395 cannot be straightforwardly construed as a proof of aerobic glycolysis or Warburg effect given
396 the compromise of O₂ supply associated with SARS-CoV-2 pneumonia. The strong induction
397 of *IRGI/ACOD1* mRNA is consistent with its dependence on IFNs [59,60]. Notably, the
398 ACOD1 product itaconate exerts antiviral activity and is considered a druggable target to
399 counter the hyperinflammatory response [61].

400 Monocytic lineage cells are key players of the innate immune response due to their
401 array of pattern recognition receptors and involvement in antigen presentation. BAAs showed
402 a low expression of markers associated with antigen presentation, survival signals, and the ISG
403 *MXI* during active infection. It is remarkable the low expression of *HLA-DRB1* mRNA, the
404 gene encoding the most prevalent β -subunit of HLA-DR. This is in accordance with the
405 decreased expression of HLA-DR in monocytes of COVID-19 patients, which drives
406 hyperinflammation and defective antigen presentation mediated by IL-6 [62]. In contrast, the
407 increased expression of *TMPRSS2* mRNA agrees with the facilitating role of this
408 transmembrane protease in viral infection by cleaving viral S glycoprotein. Tellingly, single

409 nucleotide polymorphisms at 21q22.3 locus within *TMPRSS2* and near *MX1* genes have been
410 associated with severe COVID-19 disease [35].

411 TLR7 and TLR8 are tandem duplicated genes on the X-chromosome, the function of
412 which shows some commonalities and specificities. For instance, TLR8 is not functional in
413 mice, and this explains the involvement of TLR7-induced cytokines in murine influenza [63].
414 TLR8 expression is a hallmark of human MDDCs, while TLR7 is present in monocytes,
415 macrophages, and plasmacytoid dendritic cells [33]. A pioneering study addressing the
416 pathophysiology of 2003 SARS-CoV-1 outbreak showed a unique ability of SARS-CoV-1 GU-
417 rich RNA sequences to induce proinflammatory cytokines through TLR7 in mice and TLR8 in
418 human leukocytes [64]. This notion was extended in a recent report by comparing the effect of
419 GU-rich RNAs on inflammasome activation and proinflammatory cytokine production.
420 Notably, GU-rich RNA from the SARS-CoV-2 spike protein triggered the greatest
421 inflammatory in human macrophages via TLR8 [65]. This agrees with our BAA and *in vitro*
422 studies showing TLR8 as a central element in the recognition of +ssRNA virus and suggests a
423 unique involvement of MDDCs and TLR8 in *XBPI* splicing and hyperinflammation.
424 Comparison of ssRNA40 and ssRNA41 effects show that TLR8-dependent signaling and
425 sXBP1 are critical for cytokine expression, given the lack of effect of ssRNA41.

426 Activation of TLR7 by imiquimod induced a limited set of MDDC responses. However,
427 it was remarkable the effect on energetic metabolism, characterized by a drop of the OCR and
428 a parallel increase of ECAR, which mimicked the well-known effect of bacterial
429 lipopolysaccharide. The effect on cytokines and *sXBP1* was negligible and only reached
430 significant values in the presence of palmitate. Unfortunately, our study does not contribute to
431 answer open questions regarding the actual role of TLR7 in SARS-CoV-2 defense and
432 immunopathology. TLR7 mutations driving loss-of-function in the antiviral response have
433 been associated with severe forms of COVID-19 disease in young male [28]. Another study

434 showed that while some TLR7 variants exhibit a robust loss-of-function on type I IFNs
435 production, other variants only have a marginal effect, thus suggesting that TLR7 may shape
436 the anti-viral response through additional mechanisms [66]. Moreover, autosomal inborn errors
437 of TLR3- and IRF7-dependent type I IFN immunity were found in 23 out of 659 patients with
438 severe COVID-19 pneumonia [67], thus stressing the role of type I IFNs in the protection
439 against severe forms of COVID-19 pneumonia. Our data agree with Ito et al. [68] findings,
440 who first disclosed that the TLR7/TLR8 agonist R848 was 100-fold as potent as imiquimod in
441 human MDDCs. The absence of energetic rewiring induced by ssRNA40 could be explained
442 by IFN β effect, since IFN β restrains aerobic glycolysis during mycobacteria infection. This
443 drives mitochondrial stress and helps explain why type I IFN may cause damaging effects to
444 the host [69]. Consistent with this interpretation is the lack of effect of poly(I:C), a selective
445 activator of TLR3 that by using TRIF as the sole adaptor, activates IRF3 and ultimately induces
446 type I IFNs. This is in sharp contrast with the effect of zymosan, a ligand for TLR2 and the C-
447 type lectin receptor dectin-1 [70]. The binding of sXBP1 to *IL1B*, *IL6*, and *TNF* promoters
448 induced by ssRNA40, together with the strong reduction of cytokine expression by an inhibitor
449 of IRE1 α RNase, further indicates that the IRE1 α -XBP1 branch underpins the production of
450 cytokines via TLR8. These results assign to TLR8 capacities previously reported for TLR2 and
451 TLR4, where sXBP1 is required for sustained production of proinflammatory cytokines. A
452 corollary to these results is that inhibition of IRE1 α RNase activity could be a therapeutic
453 approach for severe COVID-19 disease.

454

455 **Materials and Methods**

456

457 **Patients, Leukocyte Samples, and Ethic Statements**

458 Nasopharyngeal samples were obtained from patients studied in different medical departments
459 for symptoms consistent with SARS-CoV-2 infection at *Hospital Clínico Universitario de*
460 *Valladolid*. In the case of patients with mechanical ventilation and intubation, samples were
461 obtained by endotracheal aspirations to remove respiratory secretions as part of clinical care
462 by the attending staff. This allows the obtention of material from the alveolar and respiratory
463 bronchiole level. BAAs were directly transferred to the DNA/RNA extraction kit MagMAX™
464 Pathogen RNA/DNA (Applied Biosystems) for the automated extraction machine Kingfisher
465 Flex (Thermo Fisher Scientific). Infection diagnosis was obtained using a TaqPath™ COVID-
466 19 RT-PCR kit assay from Applied Biosystems that targets N, ORF1a, and S genes. Resolution
467 of infection was confirmed by the analysis of samples collected four days after a positive test.
468 BAAs from non-COVID-19-patients were obtained from samples collected for microbiological
469 diagnosis in patients suffering from severe bacterial pneumonia and requiring ventilatory
470 support and intubation at ICU. Lung protective ventilation of both COVID-19 and non-
471 COVID-19 patients was performed according to the current guidelines on mechanical
472 ventilation of acute respiratory distress syndrome in adult patients, which makes it unlike the
473 induction of cytokine expression by mechanical ventilation [71]. The clinical part of the study
474 was approved by the Ethics Committee of *Area de Salud Valladolid Este* (ref. PI-GR-20-2011
475 COVID). For *in vitro* experiments, MDDCs were obtained from human mononuclear cells
476 collected from pooled buffy coats of healthy donors provided by *Centro de Hemoterapia y*
477 *Hemodonación de Castilla y León Biobank*. The study was approved by the Bioethical
478 Committee of the Spanish Council of Research (CSIC) and the written informed consent of all
479 healthy donors was obtained at *Centro de Hemoterapia y Hemodonación de Castilla y León*

480 *Biobank*. The researchers received the samples in an anonymous way. The process is
481 documented by the Biobank authority according to the specific Spanish regulations. The ethics
482 committee approved this procedure before starting the study. The differentiation of monocytes
483 was carried out in the presence of GM-CSF and IL-4 for 5 days. Culture was carried out in
484 RPMI 1640 medium containing 11.1 mM D-glucose and 4 mM L-glutamine. 10% FBS was
485 maintained during the differentiation process and reduced to 2% at the start of experiments.
486 Imiquimod (Sigma-Aldrich), ssRNA40/LyoVec™, and its negative control
487 ssRNA41/LyoVec™ (InvivoGen) were used as TLR7 and TLR8 selective ligands in MDDCs.
488 MKC8866 was from MedChemExpress.

489

490 ***XBPI* Splicing Assay**

491 This was carried out by RT-PCRs using primers outside the spliced region. The PCR conditions
492 were 5 min at 95°C (hot start), 45 cycles of denaturation at 95°C for 15 s, annealing at 60°C
493 for 20 s and elongation at 72°C for 1 min. Final extension was carried out at 72°C for 5 min.
494 Gel electrophoresis was carried out in 3% agarose and *sXBPI* and *uXBPI* bands were
495 visualized by GelRed® staining and quantified using GelDoc Go Image System (Bio-Rad).

496

497 **Real-Time RT-PCR and Protein Assays**

498 Total RNA obtained by automatic extraction was used for RT reactions. The resulting cDNA
499 was amplified in a LightCycler® 480 equipment using SYBR Green I mix containing Hot Start
500 polymerase. Cycling conditions were adapted to each set of primers. *ACTB* was used as a
501 housekeeping gene to assess the relative abundance of the different mRNA using the
502 comparative cycle threshold method. The procedure was used to assay *XBPI*, *DDIT3*, *IL1B*,
503 *IL6*, *IL10*, *IL23A*, *TNF*, *SLC25A11*, *GLUT1*, *HK2*, *PFKB3*, *PDK4*, *IDH1*, *IDH2*, *SDHA*,
504 *MDH2*, *HIF1A*, *TLR7*, *TLR8*, *HLA-DRB1*, *CD300E*, *CCR2*, *MMP9*, *BATF3*, *MX1*, *OAS1*,

505 *PTGS2*, and *TMPRSS2* mRNA. Primer sequences are shown in Table 1. IL-6 and TNF α
506 proteins were assayed in supernatants of MDDCs stimulated with ssRNA40 using kits from
507 Elabscience. Pro-IL-1B was assayed by Western blot using an antibody from Cell Signaling
508 Technology.

509

510

Table 1. Sequences of primers used for qRT-PCR and ChIP assays

GENE	Forward primer	Reverse primer
<i>XBP1</i>	5'- TGAGCTGGAACAGCAAGTGG -3'	5'- ATACCGCCAGAAATCCATGGGGA -3'
<i>sXBP1</i>	5'- TGAGCTGGAACAGCAAGTGC -3'	5'- CTGCACCTGCTGCGGACTCA -3'
<i>DDIT3</i>	5'- GCAGAGATGGCAGCTGAGTC -3'	5'- AGCCAAGCCAGAGAAGCAGGGT -3'
<i>IL1B</i>	5'- ATGATGGCTTATTACAGTGGCAA -3'	5'- GTCGGAGATTCGTAGCTGGA -3'
<i>TNF</i>	5'-GTTGTAGCAAACCTCAAGC-3'	5'-TTGAAGAGGACCTGGGAGTA-3'
<i>IL6</i>	5'- TTCGGTACATCCTCGACGGC -3'	5'- TCTGCCAGTGCCTCTTTGCT -3'
<i>IL8</i>	5'- ATTTCTGCAGCTCTGTGTGAA -3'	5'- AACTTCTCCCAGCTCTTAAGT -3'
<i>IL10</i>	5'-GAGAACAGCTGCACC CAC TT-3'	5'-GGCCTTGCTCTTGT TTACAC-3'
<i>IL23A</i>	5'- GTTCCCCATATCCAGTGTGG -3'	5'- TTAGGGACTCAGGGTTGCTG -3'
<i>IL12B</i>	5'- CATGGGCCTTCATGCTATTT -3'	5'- TTTGCATTGTCAGGTTTCCA -3'
<i>IFNB1</i>	5'- TCTAGCACTGGCTGGAATGAG -3'	5'- GTTTCGGAGGTAACCTGTAAG-3'
<i>IFNG</i>	5'-CCAACGCAAAGCAATACATGA-3'	5'-CCTTTTTTCGCTTCCCTGTTTTA-3'
<i>N Gene</i>	5'- CAATGCTGCAATCGTGTAC -3'	5'- GTTGCAGTACGTGATGAGG -3'
<i>COX2</i>	5'- TTCAAATGAGATTGTGGGAA -3'	5'- AGATCATCTCTGCCTGAGTA -3'
<i>GLUT1</i>	5'- GAAGAGAGTCGGCAGATGAT -3'	5'- AATAGAAGACAGCGTTGATGC -3'
<i>HIF1A</i>	5'-AGTGTACCCTAACTAGCCGA-3'	5'-GTGCAGTGCAATACCTTCC-3'
<i>HK2</i>	5'- TAGGGCTTGAGAGCACCTGT -3'	5'- CCACCCCACTGTCACCTTTG -3'
<i>PFKFB3</i>	5'-CCGTTGGAACTGACGCAGA -3'	5'-CACAGGATCTGGGCAACGAG-3'
<i>PDK4</i>	5'- CCCGCTGTCCATGAAGCAGC -3'	5'-CCAATGTGGCTTGGGTTTCC-3'
<i>MDH2</i>	5'- TCGGCCAGAACAAATGCTAAA -3'	5'- GCGGCTTTGGTCTCGATGT -3'
<i>IDH2</i>	5'- TGGCTCAGTCTCAAGTCT -3'	5'- CTCAGCCTCAATCGTCTTCC -3'
<i>SDHA</i>	5'- CAGCATGTGTTACCAAGCT -3'	5'-GGTGTCTAGAAATGCCAC -3'
<i>SLC25A11</i>	5'- ACACCGTCTCACCTTCATC -3'	5'- CAGGGGGTAGAACAGACCAA -3'
<i>IRG1</i>	5'- GTTCCTGGGAACCACTACG -3'	5'- GATGTCTGGCTGACCCCAA -3'
<i>TLR7</i>	5'-CTTGGCACCTCTCATGCTCT-3'	5'-GTCTGTGCAGTCCACGATCA-3'
<i>TLR8</i>	5'-GCTGACCTGCATTTTCCTGC-3'	5'-CCGTTTGGGGAACCTCCTGT-3'
<i>HLA-DRB1</i>	5'-TTCCTGTGGCAGCCTAAGAG-3'	5'-AACCCCGTAGTTGTGTCTGC-3'
<i>CD300E</i>	5'-AGAGAAGGTGGAGAGGAATGG-3'	5'-AGGAAGATGGGAGGTGTGG-3'
<i>CCR2</i>	5'- CCCC AACGAGGCATAGA -3'	5'- AAGAGTCTCTGTCACTGCG -3'
<i>MMP9</i>	5'-CGTCTTCCCCTTCACTTTCC-3'	5'-CCCCACTTCTGTGCGTGT-3'
<i>BATF3</i>	5'-AGGAAGGTCCGAAGGAGAGA-3'	5'-GAGGCACTGGCACAAAGTTC-3'
<i>MX1</i>	5'-CTGGGATTTTGGGGCTTT-3'	5'-GGGATGTGGCTGGAGATG-3'
<i>OAS1</i>	5'- TCAGAAATACCCAGCCAAA-3'	5'-GAGCCACCTTTACCACCTT-3'
<i>TMPRSS2</i>	5'-CCTCTAACCTGGTGTGATGGCGT-3'	5'-TGCCAGGACTTCTCTGAGATG-3'
<i>ACTB</i>	5'-CTGTCTGGCGCACCAACCAT-3'	5'-GCAACTAAGTCATAGTCCGC-3'
ChIP Assays Primers		
PROMOTER	Forward Primer	Reverse Primer
<i>IL1B Proximal</i>	5'-TAGTTTGCTACTCTTGCCCT-3'	5'-AGGAAAGGGGAAAAGAGTATTGGT-3'
<i>IL1B Medial</i>	5'-TGAATGAAGAAAAGTATGTGCATGT-3'	5'-AAATACTGGATTTCCACGTTAG-3'
<i>IL6 Proximal</i>	5'-AGCCTCAATGACGACCTAAGC-3'	5'-GGGTGGGGCTGATTGGAAA-3'
<i>IL6 Medial</i>	5'-ACCTTCTTCATAATCCAGGC-3'	5'-AGGCTAGAATTAGCGTTCAGT-3'
<i>TNF Proximal</i>	5'-ATGCTTGTGTGTCCTCAACT-3'	5'-CAGCGGAAAACCTTCTGGTG-3'
<i>TNF Medial</i>	5'-GACCCAAACACAGGCCTCA-3'	5'-ACTAGAAGTGGGAGGGCTT-3'
<i>TNF Distal</i>	5'-GTCCAGGGCTATGGAAGTCG-3'	5'-CCCAGTGTGTGGCCATATCTT-3'

511

512

513 **Real-Time Bioenergetic Analysis**

514 Bioenergetic assays were carried out using an Agilent Seahorse XF HS Mini Analyzer. 10⁵
515 MDDCs were adhered with Cell-Tak® to Seahorse plates and treated with stimuli of TLR3,
516 TLR7, and TLR8, as well as sonicated zymosan to activate the fungal pattern receptor dectin-
517 1 and TLR2, after a stabilization period. OCR and ECAR were analyzed according to the XF
518 Cell Mito Stress Test kit protocol in XF media under the experimental conditions and in
519 response to metformin, oligomycin, FCCP, and rotenone plus antimycin A.

520

521 **Aggresome Formation Assay**

522 The formation of aggresomes due to ER stress was assayed by flow cytometry fluorescence
523 using the Proteostat® aggresome detection kit of ENZO according to the manufacturer's
524 instructions. The proteasome inhibitor MG132 was used as a positive control. MDDCs were
525 incubated under different conditions and then fixed, stained with Proteostat® dye and used for
526 the assay of fluorescence in a Gallios flow cytometer at 488 nm in the FL3 channel using the
527 Kaluza software version 1.1 for quantitative analysis (Beckman Coulter Life Sciences).

528

529 **Chromatin Immunoprecipitation (ChIP) Assay**

530 Chromatin immunoprecipitation assays were conducted using a rabbit mAb (Cell Signaling
531 Technology) against sXBP1 as previously reported [10]. Briefly, MDDCs were stimulated,
532 washed with PBS, and fixed with 1% formaldehyde. Cross-linking was terminated by 0.125 M
533 glycine. Crude nuclear extracts were collected by microcentrifugation. Chromatin sonication
534 was carried out using a Bioruptor device (Diagenode). The chromatin solution was precleared
535 by adding Protein A/G PLUS-Agarose for 30 min at 4°C under continuous rotation. After
536 elimination of the beads, mAb was added for overnight incubation at 4°C, and then Protein
537 A/G PLUS-Agarose was added and incubated for an additional period of 2 h at 4°C. Beads
538 were harvested by centrifugation at 4,000 x g and sequentially washed with lysis buffer high

539 salt, wash buffer, and elution buffer. Cross-links were reversed by heating at 67°C in a water
540 bath, and the DNA bound to the beads isolated by extraction with
541 phenol/chloroform/isoamylalcohol. Irrelevant Ab was used as control of binding specificity.
542 The sequences of the primers are shown in Table 1. Results are expressed as percentage of
543 input.

544

545 **Quantification and Statistical Analysis**

546 Data are represented as the mean \pm SEM and were analyzed with the Prism 9.0 statistical
547 program. Repeated measures one-way and two-way ANOVA analyses were performed. When
548 data did not follow normal distribution nor had equal variances, log-transformation was applied
549 before analysis. Comparison between experimental groups was carried out using unpaired or
550 paired two-tailed Student's *t*-test and Wilcoxon signed-rank test, and Welch's test. Statistical
551 details are shown in the Fig legends. Differences were considered significant for $p < 0.05$.

552

553 **ACKNOWLEDGMENTS**

554

555 José Javier Fernández is the recipient of a grant from *Junta de Castilla y León*. Cristina
556 Mancebo is the recipient of a pre-doctoral grant from the Valladolid Section of *Asociación*
557 *Española contra el Cáncer (AECC)*. *Biobanco del Centro de Hemoterapia y Hemodonación*
558 *de Castilla y León* is thanked for providing buffy coats. Staff from the Intensive Care Unit of
559 *Hospital Clínico Universitario de Valladolid* is thanked for the effort devoted to patient follow-
560 up care and sample collection. BioRender.com software was used in some figures.

561

562 **AUTHOR CONTRIBUTIONS**

563

564 **Conceptualization:** Antonio Orduña, Juan Cubillos-Ruiz, Elena Bustamante, Nieves
565 Fernández, Mariano Sánchez Crespo.

566 **Data curation:** José J. Fernández, Sonsoles Garcinuño, Gabriel March, Luis Inglada, Antonio
567 Orduña, Juan Cubillos-Ruiz, Elena Bustamante, Mariano Sánchez Crespo.

568 **Formal analysis:** José J. Fernández, Yolanda Alvarez, Luis Inglada, Jesús Blanco, Antonio
569 Orduña, Elena Bustamante, Nieves Fernández, Mariano Sánchez Crespo.

570 **Funding acquisition:** Nieves Fernández, Mariano Sánchez Crespo.

571 **Investigation:** José J. Fernández, Cristina Mancebo, Sonsoles Garcinuño, Gabriel March,
572 Yolanda Alvarez, Sara Alonso, Luis Inglada, Jesús Blanco, Antonio Orduña, Olimpio Montero,
573 Tito A. Sandoval, Juan Cubillos-Ruiz, Elena Bustamante, Nieves Fernández, Mariano Sánchez
574 Crespo.

575 **Methodology:** José J. Fernández, Cristina Mancebo, Sonsoles Garcinuño, Gabriel March,
576 Yolanda Alvarez, Sara Alonso, Olimpio Montero, Elena Bustamante, Luis Inglada, Jesús
577 Blanco, Tito A. Sandoval, Antonio Orduña, Elena Bustamante.

578 **Project administration:** Nieves Fernández.

579 **Resources:** Nieves Fernández.

580 **Supervision:** Nieves Fernández, Mariano Sánchez Crespo.

581 **Validation:** Elena Bustamante, Luis Inglada, Jesús Blanco, Elena Bustamante, Nieves
582 Fernández.

583 **Visualization:** José J. Fernández, Nieves Fernández, Mariano Sánchez Crespo.

584 **Writing – original draft:** Luis Inglada, Jesús Blanco, Tito A. Sandoval, Juan Cubillos-Ruiz,
585 Nieves Fernández, Mariano Sánchez Crespo.

586 **Writing – review & editing:** Luis Inglada, Jesús Blanco, Tito A. Sandoval, Juan Cubillos-
587 Ruiz, Elena Bustamante, Nieves Fernández, Mariano Sánchez Crespo.

588

589 **FUNDING**

590

591 This study was funded by *Fondo COVID-19 del Instituto de Salud Carlos III/Junta de Castilla*
592 *y León* (N.F.). European Commission-NextGenerationEU, through CSIC's Global Health
593 Platform (PTI Salud Global) (project SGL2103016) (M.S.C.). *Plan Nacional de Salud y*
594 *Farmacía* Grant SAF2017-83079-R and Grant PID2020-113751RB-I00 funded by
595 MCIN/AEI/ 10.13039/501100011033 (M.S.C.). *Junta de Castilla y León/Fondo Social*
596 *Europeo* Grants CSI035P17 (M.S.C.) and VA175P20 (N.F.). *Proyecto SEAHORSE*
597 *INFRARED: IR2020-1-UVA05* (JCyL). The funders had no role in study design, data
598 collection and analysis, decision to publish, or preparation of the manuscript.

599

600

601 **REFERENCES**

602

603 1. Fajgenbaum DC, June CH. Cytokine storm. *N Engl J Med*. 2020;383: 2255-2273.

604 2. Riva G, Nasillo V, Tagliafico E, Trenti T, Comoli P, Luppi M. COVID-19: more than a
605 cytokine storm. *Crit. Care*. 2020;24: 549.

606 3. Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein
607 response. *Nat Rev Mol Cell Biol*. 2012;13: 89-102.

608 4. Bettigole SE, Glimcher LH. Endoplasmic reticulum stress in immunity. *Annu Rev Immunol*.
609 2015;33: 107-138.

610 5. Chen X, Cubillos-Ruiz, JR. Endoplasmic reticulum stress signals in the tumour and its
611 microenvironment. *Nat Rev Cancer*. 2021;21: 71-88.

612 6. Calton M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, et al. IRE1 couples
613 endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA.
614 *Nature*. 2002;415: 92-96.

615 7. Chopra S, Giovanelli P, Alvarado-Vazquez PA, Alonso S, Song M, Sandoval TA, et al.
616 IRE1 α -XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain.
617 *Science*. 2019;365(6450): eaau6499.

618 8. Martinon F, Chen X, Lee AH, Glimcher LH. TLR activation of the transcription factor XBP1
619 regulates innate immune responses in macrophages. *Nat Immunol*. 2011;11: 411-418.

620 9. Zeng L, Liu YP, Sha H, Chen H, Qi L, Smith JA. XBP-1 couples endoplasmic reticulum
621 stress to augmented IFN- β induction via a *cis*-acting enhancer in macrophages. *J*
622 *Immunol*. 2010;185: 2324-2330.

623 10. Márquez S, Fernández JJ, Terán-Cabanillas E, Herrero C, Alonso S, Azogil A, et al.
624 Endoplasmic reticulum stress sensor IRE1 α enhances IL-23 expression by human
625 dendritic cells. *Front Immunol*. 2017;8: 639.

626 11. Mogilenko DA, Haas JT, L'homme L, Fleury S, Quemener S, Levvasseur, et al. Metabolic
627 and innate immune cues merge into a specific inflammatory response via the UPR. *Cell*.
628 2019;177: 1201-1216.

629 12. Keestra-Gounder AM, Byndloss MX, Seyffert N, Young BM, Chávez-Arroyo A, Tsai AY,
630 et al. NOD1 and NOD2 signalling links ER stress with inflammation. *Nature*. 2016;532:
631 394-397.

- 632 13. Qiu Q, Zheng Z, Chang L, Zhao YS, Tan C, Dandekar A, et al. Toll-like receptor-mediated
633 IRE1 α activation as a therapeutic target for inflammatory arthritis. *EMBO J.* 2013;32:
634 2477-2490.
- 635 14. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, et al.
636 Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models
637 of inflammation and sepsis. *Sci Transl Med.* 2019;11(478):eaau5266.
- 638 15. Sule G, Abuaita BH, Steffes PA, Fernandes AT, Estes SK, Dobry C, et al. Endoplasmic
639 reticulum stress sensor IRE1 α propels neutrophil hyperactivity in lupus. *J Clin Invest.*
640 2021;131(7):e137866.
- 641 16. Prasad, V, Suomalainen M, Jasiqi Y, Hemmi S, Hearing P, Hosie L, et al. The UPR sensor
642 IRE1 α and the adenovirus E3-19K glycoprotein sustain persistent and lytic infections.
643 *Nat Commun.* 2020;11: 1997.
- 644 17. Prasad V, Greber UF. The endoplasmic reticulum unfolded protein response - homeostasis,
645 cell death and evolution in virus infections. *FEMS Microbiol Rev.* 2021;45: fuab016.
- 646 18. Hrinčius ER, Liedmann S, Finkelstein D, Vogel P, Gansebom S, Samarasinghe AE, et al.
647 Acute lung injury results from innate sensing of viruses by an ER stress pathway. *Cell*
648 *Rep.* 2015;11: 1591-1603.
- 649 19. Rosa-Fernandes L, Lazari LC, Macedo da Silva J, de Moraes Gomes V, Guaragna Machado
650 RR, Ferreira dos Santos A, et al. SARS-CoV-2 activates ER stress and unfolded protein
651 response. *bioRxiv.* 2021;doi: <https://doi.org/10.1101/2021.06.21.449284>.
- 652 20. Liu N, Jiang C, Cai P, Shen Z, Sun W, Xu H, et al. Single-cell analysis of COVID-19,
653 sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive
654 signatures in monocytes. *Cell Rep.* 2021;37: 109793.
- 655 21. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Möller R, et al.
656 Imbalanced host response to SARS-CoV-2 drives development of COVID-19. *Cell.*
657 2020;81: 1036–1045.
- 658 22. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19
659 patients with tocilizumab. *Proc Natl Acad Sci USA.* 2020;117: 10970-10975.
- 660 23. Acosta-Alvear D, Zhou Y, Blais A, Tsikitis M, Lents NH, Arias C, et al. XBP1 controls
661 diverse cell-type and condition-specific transcriptional regulatory networks. *Mol Cell.*
662 2007;27: 53-66.
- 663 24. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et
664 al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell
665 homeostasis. *Cell.* 2015;161: 1527-1538.
666

- 667 25. Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, et al. IRE1 α -XBP1
668 controls T cell function in ovarian cancer by regulating mitochondrial activity. *Nature*.
669 2018;562: 423-428.
- 670 26. Echavarría-Consuegra L, Cook GM, Busnadiego I, Lefèvre C, Keep S, Brown K, et al.
671 Manipulation of the unfolded protein response: A pharmacological strategy against
672 coronavirus infection. *PLoS Pathog*. 2021;17(6):e1009644.
- 673 27. Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, et al. Cannabidiol inhibits
674 SARS-CoV-2 replication through induction of the host ER stress and innate immune
675 responses. *Sci Adv*. 2022 Jan 20:6110. Epub ahead of print. PMID: 35050692.
676
- 677 28. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten
678 S, et al. Presence of genetic variants among young men with severe COVID-19. *JAMA*.
679 2020;324: 1-11.
- 680 29. Rodríguez M, Domingo E, Alonso S, Frade JG, Eiros J, Sánchez Crespo M, et al. The
681 unfolded protein response and the phosphorylations of activating transcription factor 2
682 in the trans-activation of *IL23A* promoter produced by β -glucans. *J Biol Chem*.
683 2014;289: 22942-22957.
- 684 30. Turini ME, DuBois RN. Cyclooxygenase-2: A Therapeutic Target. *Annu Rev Med*.
685 2002;53: 35-57.
- 686 31. Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et
687 al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response
688 through a HIF-1 α /glycolysis-dependent axis. *Cell Metab*. 2020;32: 437-446.
- 689 32. O'Carroll SM, O'Neill LAJ. Targeting immunometabolism to treat COVID-19. *Immunother*
690 *Adv*. 2021;1: ltab013.
- 691 33. Song R, Gao Y, Dozmorov I, Malladi V, Saha I, McDaniel MM, et al. IRF1 governs the
692 differential interferon-stimulated gene responses in human monocytes and
693 macrophages by regulating chromatin accessibility. *Cell Rep*. 2021;34: 108891.
- 694 34. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-
695 CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven
696 protease inhibitor. *Cell*. 2020;181: 271-280.
- 697 35. Andolfo I, Russo R, Lasorsa VA, Cantalupo S, Rosato BE, Bonfiglio F, et al. Common
698 variants at 21q22.3 locus influence *MXI* and *TMPRSS2* gene expression and
699 susceptibility to severe COVID-19. *iScience*. 2021;24: 102322.
- 700 36. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I
701 interferon activity and inflammatory responses in severe COVID-19 patients. *Science*.
702 2020;369: 718-724.

- 703 37. Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of
704 TNF- α and IFN- γ triggers inflammatory cell death, tissue damage, and mortality in
705 SARS-CoV-2 infection and cytokine shock syndromes. *Cell*. 2021;184: 149-168.e17.
- 706 38. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon- γ -related cytokine
707 storm in SARS patients. *J Med Virol*. 2005;75: 185-194.
- 708 39. Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, Lo Cascio A, et al. Type III
709 interferons disrupt the lung epithelial barrier upon viral recognition. *Science*. 2020;369:
710 706-712.
- 711 40. Gao DK, Salomonis N, Henderlight M, Woods C, Thakkar K, Grom AA, et al. IFN- γ is
712 essential for alveolar macrophage driven pulmonary inflammation in macrophage
713 activation syndrome. *JCI Insight*. 2021;27: 147593.
- 714 41. Verma AK, Bauer C, Palani S, Metzger DW, Sun K. IFN- γ drives TNF- α hyperproduction
715 and lethal lung inflammation during antibiotic treatment of postinfluenza
716 staphylococcus aureus pneumonia. *J Immunol*. 2021;207: 1371-1376.
- 717 42. Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1
718 splicing by inhibition of IRE1 α is a promising therapeutic option in multiple myeloma.
719 *Blood*. 2012;119: 5772-5781.
- 720 43. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like
721 receptor-induced changes in glycolytic metabolism regulate dendritic cell activation.
722 *Blood*. 2010;115: 4742-4749.
- 723 44. Xian H, Liu Y, Rundberg Nilsson A, Gatchalian R, Crother TR, Tourtellotte WG, et al.
724 Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3
725 inflammasome activation and pulmonary inflammation. *Immunity*. 2021;54: 1463-
726 1477.e11.
- 727 45. Kelly B, Tannahill GM, Murphy MP, O'Neill LA. Metformin inhibits the production of
728 reactive oxygen species from NADH:ubiquinone oxidoreductase to limit induction of
729 interleukin-1 β (IL-1 β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-
730 activated macrophages. *J Biol Chem*. 2015;290: 20348-20359.
- 731 46. Baselski VS, Wunderink RG. Bronchoscopic diagnosis of pneumonia. *Clin Microbiol Rev*.
732 1994;7: 533-558.
- 733 47. Shin YM, Oh YM, Kim MN. Usefulness of quantitative endotracheal aspirate cultures in
734 intensive care unit patients with suspected pneumonia. *J Korean Med Sci*. 2011;26: 865-
735 869.


- 736 48. Pickens C, Wunderink RG, Qi C, Mopuru H, Donnelly H, Powell K, et al. A multiplex
737 polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia.
738 *Diagn Microbiol Infect Dis.* 2020;98: 115179.
- 739 49. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened innate immune responses
740 in the respiratory tract of COVID-19 patients. *Cell Host Microbe.* 2020;27: 883-890.
- 741 50. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of
742 bronchoalveolar immune cells in patients with COVID-19. *Nat. Med.* 2020;26: 842-
743 844.
- 744 51. Szabo PA, Dogra P, Gray JJ, Wells SB, Connors TJ, Weisberg SP, et al. Developmental
745 regulation of effector and resident memory T cell generation during pediatric viral
746 respiratory tract infection. *J Immunol.* 2018;201: 432-439.
- 747 52. Connors TJ, Baird JS, Yopes MC, Zens KD, Pethe K, Ravindranath TM, et al.
748 Developmental regulation of effector and resident memory T cell generation during
749 pediatric viral respiratory tract Infection. *J Immunol.* 2018;201: 432-439.
- 750 53. Connors TJ, Ravindranath TM, Bickham KL, Gordon CL, Zhang F, Levin B, et al. Airway
751 CD8(+) T cells are associated with lung injury during infant viral respiratory tract
752 infection. *Am J Respir Cell Mol Biol.* 2016;54: 822-830.
- 753 54. Sarma A, Christenson SA, Byrne A, Mick E, Pisco AO, DeVoe C, et al. Tracheal aspirate
754 RNA sequencing identifies distinct immunological features of COVID-19 ARDS. *Nat*
755 *Commun.* 2021;12:5152.
- 756 55. Sinha P, Matthay MA, Calfee CS. Is a "Cytokine Storm" relevant to COVID-19? *JAMA*
757 *Intern Med.* 2020;180:1152-1154.
- 758 56. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically
759 ill patients with COVID-19 and other conditions. *JAMA.* 2020;324:1565-1567.
- 760 57. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine
761 vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A
762 randomized clinical trial. *JAMA.* 2020;324: 2292-2300.
- 763 58. Reis G, dos Santos Moreira-Silva EA, Medeiros Silva DC, Thabane L, Cruz Milagres A,
764 Santiago Ferreira T, et al. Effect of early treatment with fluvoxamine on risk of
765 emergency care and hospitalisation among patients with COVID-19: the TOGETHER
766 randomised, platform clinical trial. *Lancet Glob Health* 2022 Jan;10(1):e42-e51.
767
- 768 59. Shi S, Blumenthal A, Hickey CM, Gandotra S, Levy D, Ehrt S. Expression of many
769 immunologically important genes in *Mycobacterium tuberculosis*-infected
770 macrophages is independent of both TLR2 and TLR4 but dependent on IFN- $\alpha\beta$ receptor
771 and STAT1. *J Immunol.* 2005;175: 3318-3328.

- 772 60. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. Immune-
773 responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid
774 production. *Proc Natl Acad Sci USA*. 2013;110: 7820-7825.
- 775 61. Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. The
776 immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome
777 activation. *Cell Metab*. 2020;32: 468-478.
- 778 62. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
779 Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe
780 respiratory failure. *Cell Host Microbe*. 2020;27: 992-1000.e3.
- 781 63. Rappe JCF, Finsterbusch K, Crotta S, Mack M, Priestnall SL, Wack A. A TLR7 antagonist
782 restricts interferon-dependent and -independent immunopathology in a mouse model of
783 severe influenza. *J Exp Med*. 2021;218: e20201631.
- 784 64. Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA
785 identified from SARS coronavirus contributes an excessive innate immune response.
786 *Microbes Infect*. 2013;15: 88-95.
- 787 65. Campbell GR, To RK, Hanna J, Spector SA. SARS-CoV-2, SARS-CoV-1, and HIV-1
788 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages
789 through a non-classical pathway. *iScience*. 2021;24: 102295.
- 790 66 Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, et al. Association of
791 Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings
792 from a nested case-control study. *Elife*. 2021;10: e67569.
- 793 67. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type
794 I IFN immunity in patients with life-threatening COVID-19. *Science*. 2020;370:
795 eabd4570.
- 796 68. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon- α and
797 interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood
798 dendritic cell subsets. *J Exp Med*. 2002;195: 1507-1512.
- 799 69. Olson GS, Murray TA, Jahn AN, Mai D, Diercks AH, Gold ES, et al. Type I interferon
800 decreases macrophage energy metabolism during mycobacterial infection. *Cell Rep*.
801 2021;35: 109195.
- 802 70. Thwe PM, Fritz DI, Snyder JP, Smith PR, Curtis KD, O'Donnell A, et al. Syk-dependent
803 glycolytic reprogramming in dendritic cells regulates IL-1 β production to β -glucan
804 ligands in a TLR-independent manner. *J Leukoc Biol*. 2019;106: 1325-1335.
- 805 71. Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al. An Official
806 American Thoracic Society/European Society of Intensive Care Medicine/Society of

807 Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult
808 Patients with Acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med.*
809 2017;195: 1253-1263.

810

811



812

813

814

815

816

817

818

819

820

821

822

823


824

825

826

827

Fig 1. Sequences of *XBPI* mRNA transcripts and analysis of RT-PCR products in nasopharyngeal samples. (A) Medical departments involved in the obtention of nasopharyngeal swabs. (B) The splicing of 26 nucleotides in NM_005080.4 sequence generates the 531-549 sequence in NM_001079539.2. The position of primers, including the reverse primer spanning the spliced sequence is shown. (C) Agarose gel electrophoresis and sequencing of the amplicons obtained by RT-PCR with *XBPI* primers showing the migration of the spliced (*sXBPI*) and unspliced products (*uXBPI*). (D) The electrophoretic pattern of *XBPI* in a series of samples from COVID-19 negative and positive patients is shown. The presence of three bands in some cases is due to the formation of heteroduplexes. (E) Distribution of patients according to the presence or absence of *sXBPI* in SARS-CoV-2 negative and positive patients. (F) Quantitation of *sXBPI* versus total *XBPI* ($XBPI^T$) in COVID-19 positive and negative samples. (G) Quantitation of *sXBPI* versus total *XBPI* in male and female SARS-CoV-2 positive patients. (H) Age distribution of patients with *sXBPI*. (I) Quantitation of *sXBPI* versus total *XBPI* in SARS-CoV-2 positive according to the outcome. * $p < 0.05$, *** $p < 0.005$, paired or unpaired (two-tail) *t* test.



828

829

830 **Fig 2. Expression of the mRNA of *XBP1*, *DDIT3/CHOP*, and cytokines in BAAs of**
 831 **patients under mechanical ventilation in ICU.** (A) Scheme of sample collection. (B)
 832 Stratification of patients according to non-COVID-19, active COVID-19, and non-active
 833 COVID-19 infection. (C) *sXBP1* expression in the different cohorts. Results are expressed as
 834 mean ± SEM. †Ordinary one-way ANOVA with the Tukey's multiple comparisons test. *p <
 835 0.05. *** p < 0.005. (D) Expression of the mRNA de *DDIT3/CHOP*. ‡Kruskal-Wallis U test.
 836 (E-N) Expression of the mRNA encoding *IL1B*, *TNF*, *IL6*, *IL8*, *IL10*, *IL12A*, *IL12B*, *IL23A*,
 837 *IFNB1*, and *IFNG* in BAAs. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01,
 838 ***p < 0.005. †Ordinary one-way ANOVA. ‡Kruskal-Wallis U test. ††Welch and Brown-
 839 Forsythe ANOVA test.

840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888






Fig 3. Association of *sXBP1* splicing and viral replication with cytokine expression in BAAs. (A) Viral load in samples obtained at the time of SARS-CoV-2 positive and negative tests. Data are presented as mean \pm SEM. ** $p < 0.01$. Unpaired two-tailed Student's *t* test. (B-I) Patients were stratified in cohorts according to the presence of *sXBP1* and the presence or absence of viral load as deemed from RT-PCR test for SARS-CoV-2 infection. The mRNA of *PTGS2* and various cytokines was assayed in the extracted RNA and the statistical significance of the results was assayed using ordinary one-way ANOVA with Tukey's post-hoc multiple comparison test. Data are presented as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$. §One-sample Wilcoxon signed rank test. ¶Unpaired (two-tail) *t* test. #Welch's test.


889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920



921 **Fig 4. Expression of enzymes involved in glycolysis and mitochondrial proteins.** (A)
 922 Diagram of glycolytic and mitochondrial proteins assayed in BAAs. (B-K) BAAs of patients
 923 with controlled respiration were used for RNA extraction and RT-PCR assay of mRNA
 924 expression of genes encoding for proteins involved in glycolysis, response to hypoxia, and
 925 mitochondrial function. *GLUT1*, glucose transporter 1. *HIF1A*, hypoxia-inducible factor 1 α .
 926 *HK2*, hexokinase 2. *PFKFB3*, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. *PDK4*,
 927 pyruvate dehydrogenase kinase. *MDH2*, malate dehydrogenase 2. *IDH2*, isocitrate
 928 dehydrogenase 2. *SDHA*, succinate dehydrogenase protein subunit A. *SLC25A11*, mitochondrial
 929 2-oxoglutarate-malate carrier. *IRG1-ACOD1*, immunoresponsive gene 1-aconitate
 930 decarboxylase. Data are presented as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$.
 931 ‡Kruskal-Wallis U test. †Ordinary one-way ANOVA. ¶Paired or unpaired (two-tail) t test.
 932



934 **Fig 5. Expression of genes involved in monocytic-lineage differentiation in BAAs.** (A)
935 Expression of the mRNA encoding the receptors TLR7 and TLR8 in patients with active
936 SARS-CoV-2 infection and after negative tests. (B-F) Expression of monocyte-differentiation
937 markers in BAAs of non-COVID-19, COVID-19, and post-COVID-19 infection. (G-H)
938 Expression of the ISG *MX1* and *OAS1* mRNA. (I) Expression of the mRNA encoding
939 *PTGS2/COX2*. (J) Expression of the mRNA encoding the transmembrane serine protease
940 *TMPRSS2*. Data are presented as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$. †Ordinary
941 one-way ANOVA. ‡Kruskal-Wallis *U* test. §Holm-Sidak's multiple comparison test.
942




943

944 **Fig 6. Expression of TLR7 and TLR8 receptors in MDDCs and response to the TLR7**
 945 **agonist imiquimod.** (A) Expression of the mRNA encoding TLR7 and TLR8 in MDDCs. (B)
 946 Effect of 5 $\mu\text{g/ml}$ imiquimod on *sXBP1* in the presence and absence of 0.5 mM palmitate (PA)
 947 and 10 mM 2-deoxyglucose (2-DG). MDDCs were incubated for one hour in the presence of
 948 the indicated additions and then stimulated with imiquimod for 1 hour. At the end of this time,
 949 the RNA was extracted and used for the assay of *sXBP1*. (C-F) Effect of imiquimod on the
 950 expression of the mRNA encoding *IL1B*, *TNF*, *IL6*, and *IL23A*. The stimulation with

951 imiquimod was maintained for four hours before RNA extraction. Data are presented as mean
952 \pm SEM. * $p < 0.05$, ** $p < 0.01$. (G-J) Effect of MKC8866 and fluvoxamine on the expression
953 of the mRNA encoding *IFNB1*, *IFNG*, *MX1*, and *OAS1*. MDDCs were preincubated with 10
954 μ M MKC8866 and 20 μ M fluvoxamine for one hour and then stimulated with 5 μ g/ml
955 imiquimod for 4 hours. At the end of this time, the RNA was extracted and used for mRNA
956 assay. (K) Effect of imiquimod on O₂ consumption rate (OCR) and glycolysis assayed as
957 extracellular acidification rate (ECAR). Data are presented as mean \pm SEM. * $p < 0.05$, *** $p <$
958 0.005, paired, (two-tail) Student's *t* test. (L) Seahorse real-time metabolic analysis of one
959 experiment where MDDCs were stimulated with imiquimod and then treated with 2 μ M FCCP
960 (an uncoupler of oxidative phosphorylation) to estimate maximal respiratory rate, and the
961 combination 0.5 μ M rotenone/antimycin (Rot/AA) to inhibit complex I and complex III of the
962 mitochondrial electron transport chain. Where indicated, metformin was used to inhibit
963 complex I activity. (M) MDDCs were treated with imiquimod or with poly(I:C) to show the
964 effect of a TLR3 agonist.

965



968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996

Fig 7. Effect of the TLR8 agonist ssRNA40 on MDDCs. (A) Effect of ssRNA40 and IRE1 α RNase inhibitors on *sXBP1*. The RNA was collected after one hour of incubation with 10 μ M MKC8866 or 20 μ M 4 μ 8C and one hour of stimulation with 2 μ g/ml of either ssRNA40 or ssRNA41 and used for the assay of *uXBP1* and *sXBP1*. (B-D) Effect of 10 μ M MKC8866 on the mRNA expression of *IL1B*, *TNF*, and *IL6* mRNA. MDDCs were maintained for one hour in the presence of MKC8866 and then stimulated with ssRNA40 or ssRNA41 for 4 hours, prior to the extraction of the RNA for cytokine assays. Data are presented as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$. §Wilcoxon matched pairs signed rank test. ¶Paired *t* test two-ways. (E and F) Effect of MKC8866 on the expression of IL-6 and TNF α protein. MDDCs were preincubated with MKC8866 for one hour and then stimulated overnight with ssRNA40. At the end of this period, supernatants were collected for cytokine ELISA assay. Data are presented as mean \pm SEM. * $p < 0.05$. (G) Induction of the expression of pro-IL-1 β by ssRNA40 and effect of MKC8866. MDDCs were treated as in the ELISA assays and after overnight incubation, cell extracts were collected and used for the assay of pro-IL-1 β and β -actin proteins by Western blot. β -actin was used for normalization. A.U., arbitrary units. (H-K) Effect of MKC8866 and fluvoxamine on the expression of the mRNA encoding *IFNB1*, *IFNG*, *MX1* and *OAS1*. MDDCs were preincubated with 10 μ M MKC8866 and 20 μ M fluvoxamine for one hour and then stimulated with 2 μ g/ml ssRNA40 for 4 hours. At the end of this time, the RNA was extracted for mRNA assay. Data are presented as mean \pm SEM. * $p < 0.05$. ††Ratio paired *t* test. ¶Paired *t* test two-ways. ‡‡Mann Whitney test. (L-N) Effect of ssRNA40 on the binding of sXBP1 to the promoters of *IL1B*, *IL6*, and *TNF*. The captions below the graphs indicate the distance from transcription start to the nucleotide positions where PCR primers were selected. The defined sXBP1 binding sites included in the regions spanned by the primers are indicated. Samples were obtained after one hour stimulation by 2 μ g/ml ssRNA40. Data are presented as mean \pm SEM. * $p < 0.05$. ††Ratio paired *t* test.